Greggs is to target customers on weight-loss drugs by rolling out smaller portions and protein-rich alternatives as it battles a slowdown in sales. Roisin Currie, the chief executive, said there was “no doubt” that the injections were changing “what and how” people eat, and that the bakery chain was looking at adapting its range to suit these customers. It came as shares in Greggs plunged to their lowest level since the pandemic after it said weaker demand for its sausage rolls and other baked goods dealt a £10m blow to profits. Ms Currie said: “If anyone is on a GLP-1 [weight-loss drug], we know they still need to eat, but what they need to eat starts to change and the portions that they start to eat are changing. “That’s really important for us and making sure that we have got a variety of protein-led options in our range, and also making sure that we’ve got some of the snack products that customers are looking for if they are on any of the GLP-1 drugs.” So-called GLP-1 weight loss drugs are named after the hormone they mimic in the brain which helps curb appetite and create a feeling of being fuller for longer. Greggs said on Tuesday it had endured a “challenging start to 2025” as it posted a 14pc slump in profits to £63.5m in the first half of the year. Sales grew by 7pc compared with a year ago but it marked a slowdown from 11pc during the same period in 2024. The company blamed higher costs as well as “heavy snow and strong winds” and the recent heatwave for decline in customers visiting its stores. Ms Currie said: “Hot food doesn’t sell well in those [high] temperatures. We know that people eat less when it starts to get to those temperatures.” Shares slumped as much as 9pc to £15 following the announcement, later recovering some of their losses. The company is now worth 40pc less than it was since the start of the year as investors grow wary over whether demand for Greggs is waning. Greggs said it shut 56 stores in the first half of the year, which included the relocation of 27 sites. Greggs said it had also opened 87 stores during the period and was on track to 3,000 UK shops in the future. It currently has 2,649 stores. Ms Currie denied the UK had reached “peak Greggs” and maintained that there was “significant opportunity” to open new stores in areas such as supermarkets, retail parks and transport hubs. She said the store closures were in line with previous years as it assessed its estate for where it continued to grow. Ms Currie said Greggs had “the flexibility that if you see a catchment has changed, or high street has changed”, then it was able to move sites. 繼續閱讀 The move to push ahead with store openings comes despite analysts saying its expansion targets were too ambitious. Peel Hunt recently raised concerns over its growth plans, saying: “This implies store densities of one Greggs for every 19,000 people, which comes well ahead of McDonald’s store estate and ahead of Costa.” 查看留言
Greggs to target customers on weight-loss drugs
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...